Trial record 1 of 48 for:
Saved Studies
A Study of AKCEA-APOCIII-LRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS) (BALANCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04568434 |
|
Recruitment Status :
Recruiting
First Posted : September 29, 2020
Last Update Posted : February 2, 2021
|
Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
Akcea Therapeutics
Information provided by (Responsible Party):
Ionis Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the study is to evaluate the efficacy of AKCEA-APOCIII-LRx as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Familial Chylomicronemia Syndrome | Drug: AKCEA-APOCIII-LRx Drug: Placebo | Phase 3 |
This is a multi-center, double-blind, Phase 3 study in up to 60 patients with FCS. Participants will be randomized in a 2:1 ratio to receive AKCEA-APOCIII-LRx or matching placebo in a 53-week treatment period. The length of participation in the study is approximately 74 weeks, which includes an up to 8-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period. Following the treatment period, eligible patients may have the option of enrolling in an open label extension study.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) |
| Actual Study Start Date : | November 18, 2020 |
| Estimated Primary Completion Date : | March 2023 |
| Estimated Study Completion Date : | June 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Familial lipoprotein lipase deficiency
| Arm | Intervention/treatment |
|---|---|
|
Experimental: AKCEA-APOCIII-LRx
AKCEA-APOCIII-LRx will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
|
Drug: AKCEA-APOCIII-LRx
AKCEA-APOCIII-LRx will be administered by SC injection.
Other Name: ISIS 678354 |
|
Placebo Comparator: Placebo
AKCEA-APOCIII-LRx-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
|
Drug: Placebo
AKCEA-APOCIII-LRx-matching placebo will be administered by SC injection. |
Primary Outcome Measures :
- Percent Change from Baseline in Fasting TG at 6 Months (average of Weeks 23, 25, and 27) compared to placebo [ Time Frame: Baseline and Month 6 ]
Secondary Outcome Measures :
- Percent Change from Baseline in Fasting TG at 12 months (average of Weeks 51 and 53) compared to placebo [ Time Frame: Baseline and Month 12 ]
- Change from Baseline in the Proportion of Participants who Achieve ≥ 40% Reduction in Fasting TG at 6 Months Compared to Placebo [ Time Frame: Baseline and Month 6 ]
- Percent Change form Baseline in Fasting Apolipoprotein B-48 (apoB-48) at 6 Months Compared to Placebo [ Time Frame: At Month 6 ]
- Proportion of Participants who Achieve Fasting TG ≤ 750 mg/dL at 6 Months compared to placebo [ Time Frame: At Month 6 ]
- Adjudicated Acute Pancreatitis Event Rate during the Treatment Period Compared to Placebo, in Participants with ≥ 2 Events of Adjudicated Acute Pancreatitis in 5 Years prior to Enrollment [ Time Frame: Week 1 through Week 53 ]
- Adjudicated Acute Pancreatitis Event Rate during the Treatment Period Compared to Placebo [ Time Frame: Week 1 through Week 53 ]
- Change from Baseline in the Proportion of Participants who Achieve ≥ 70% Reduction in Fasting TG at 6 Months Compared to Placebo [ Time Frame: Baseline and Month 6 ]
- Proportion of Participants who Achieve Fasting TG ≤ 500 mg/dL at 6 Months Compared to Placebo [ Time Frame: At Month 6 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- A diagnosis of genetically confirmed Familial Chylomicronemia Syndrome (type 1 Hyperlipoproteinemia)
- Fasting TG ≥ 880 mg/dL (10 millimoles per liter (mmol/L)) at Screening
- History of pancreatitis
- Stable doses of statins, omega-3 fatty acids, fibrates, or other lipid-lowering medications are allowed
Key Exclusion Criteria:
- Acute coronary syndrome within 6 months of Screening
- Major surgery within 3 months of Screening
- Have any other conditions, which, in the opinion of the Investigator would make the participant unsuitable for inclusion, or could interfere with participating in or completing the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04568434
Contacts
| Contact: Ionis Pharmaceuticals | 800-679-4747 | patients@ionisph.com |
Locations
| United States, California | |
| IONIS Investigative Site | Recruiting |
| Huntington Beach, California, United States, 92648 | |
| United States, Florida | |
| IONIS Investigative Site | Recruiting |
| Boca Raton, Florida, United States, 33434 | |
| United States, Kansas | |
| IONIS Investigative Site | Recruiting |
| Kansas City, Kansas, United States, 66160 | |
| United States, Texas | |
| IONIS Investigative Site | Recruiting |
| Houston, Texas, United States, 77030 | |
| United States, Virginia | |
| IONIS Investigative Site | Recruiting |
| Norfolk, Virginia, United States, 23510 | |
| Canada, Quebec | |
| IONIS Investigative Site | Recruiting |
| Chicoutimi, Quebec, Canada, G7H 7K9 | |
| IONIS Investigative Site | Recruiting |
| Québec, Quebec, Canada, G1V 4W2 | |
Sponsors and Collaborators
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics
| Responsible Party: | Ionis Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT04568434 |
| Other Study ID Numbers: |
ISIS 678354-CS3 2020-002536-67 ( EudraCT Number ) |
| First Posted: | September 29, 2020 Key Record Dates |
| Last Update Posted: | February 2, 2021 |
| Last Verified: | January 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
Keywords provided by Ionis Pharmaceuticals, Inc.:
|
FCS |
Additional relevant MeSH terms:
|
Hyperlipoproteinemia Type I Syndrome Disease Pathologic Processes Lipid Metabolism, Inborn Errors Metabolism, Inborn Errors |
Genetic Diseases, Inborn Hyperlipoproteinemias Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |